Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients

  • Xiaojun Bi (毕小军)
  • Youbin Deng (邓又斌)
  • Fanjing Zeng (曾繁静)
  • Ying Zhu (朱 英)
  • Yuhan Wu (伍玉晗)
  • Ceyao Zhao (赵策瑶)
  • Chunlei Li (黎春雷)


The value of two-dimensional strain echocardiography for assessing left ventricular regional systolic function in breast cancer patients who were treated with epirubicin was evaluated. A total of 116 breast cancer patients were divided into 3 groups: Thirty-eight patients in group A were given epirubicin (Epi) of 120–340 mg/m2, 42 patients in group B received epirubicin of ≥ 360 mg/m2, and 36 patients after surging without chemotherapy served as the control group C. High frame rate two-dimensional images were recorded from apical long-axis view, four-chamber view, two-chamber view of left ventricle. Peak systolic strain of left ventricular subendocardial myocardium was measured using two-dimensional strain software. The conventional echocardiographic parameters were also obtained. Conventional echocardiography showed there was no significant changes in conventional echocardiographic parameters among the three groups (P>0.05). Two-dimensional strain echocardiography revealed that the peak systolic strain of left ventricular subendocardial myocardium in group A was reduced in some segments as compared with the controls (P<0.05). The peak systolic strain of left ventricular subendocardial myocardium in group B was reduced significantly as compared with group C (P<0.05), but that was reduced in group B just in some of the segments as compared with group A (P<0.05). It was concluded that two-dimensional strain echocardiography could early and sensitively display the effects of epirubicin-induced cardiotoxicity on the systolic function of left ventricular subendocardial myocardium, and early monitor the epirubicin-induced cardiotoxicity.

Key words

echocardiography epirubicin cardiotoxicity breast cancer subendocardial myocardium two-dimensional strain 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Altman DG. Prognostic models: a methodological framework and review of models for breast cancer. Cancer Invest, 2009,27(3):235–243PubMedCrossRefGoogle Scholar
  2. 2.
    Kremer LC, Vam-Dalen EC, Offringa M, et al. Anthracycaline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol, 2001, 19(1):191–196PubMedGoogle Scholar
  3. 3.
    Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist, 2008, 13(12):1224–1234PubMedCrossRefGoogle Scholar
  4. 4.
    Hrdina R, Gersl V, Klimtova I, et al. Anthracycline-induced cardiotoxicity. Acta Medica (HradecKralove), 2000,43(3):75–82Google Scholar
  5. 5.
    Suzuki J, Yanagisawa A, Shiqeyama T, et al. Early detection of anthracycline-induced cartdiotoxicity by radionuclide angiocardiography by radionuclide angiocardiography. Angiology, 1999,50(1):37–45PubMedCrossRefGoogle Scholar
  6. 6.
    Gennari A, Pronzato P. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations. Clin Breast Cancer, 2008,8(Suppl 4):S179–S183PubMedCrossRefGoogle Scholar
  7. 7.
    Di Leo A, Moretti E. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol, 2008,26(31):5011–5013PubMedCrossRefGoogle Scholar
  8. 8.
    Radulescu D, Pripon S, Radulescu LI, et al. Left ventricular diastolic performance in breast cancer survivors treated with anthracyclines. Acta Cardiol, 2008, 63(1):27–32PubMedCrossRefGoogle Scholar
  9. 9.
    Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst, 2008, 100(15):1058–1067PubMedCrossRefGoogle Scholar
  10. 10.
    Zekri JM, El-Helw LM, Purohit OP, et al. Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function. Clin Oncol (R Coll Radiol), 2008,20(7):513–516Google Scholar
  11. 11.
    Adams MJ, Lipshultz SE. Pathophysiology of anthracycline and radiation associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer, 2005,44(7):600–606PubMedCrossRefGoogle Scholar
  12. 12.
    Singal PK, Lliskovic N. Doxorubicin—induced Cardiomyopathy. N Engl J Med, 1998,339(13): 900–905PubMedCrossRefGoogle Scholar
  13. 13.
    Ichinose I, Hamada Y, Mitsuyama S, et al. Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer. Chemotherapy, 2008, 54(5):379–85PubMedCrossRefGoogle Scholar
  14. 14.
    Hershman DL, Neugut AI. Anthracycline cardiotoxicity: one size does not fit all! J Natl Cancer Inst, 2008,100(15):1046–1047PubMedCrossRefGoogle Scholar
  15. 15.
    Pan XF, Wang K, Zhao XL, et al. Clinical significance of investigating myocardial transmural heterogeneity by integrated backscatter in patients with chronic ischemic dysfunctional myocardium. Chin J Ultras Med (Chinese), 2005,21(3):175–179Google Scholar
  16. 16.
    Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestation suggesting a restrictive endomyocardial disease. Br Heart J, 1986,55(3):274–282PubMedCrossRefGoogle Scholar
  17. 17.
    Jurcut R, Wildiers H, Ganame J, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr, 2008,21(12): 1283–1289PubMedCrossRefGoogle Scholar
  18. 18.
    Hashimoto I, Li X, Hejmadi Bhat A, et al. Myocardial strain rate is a superior method for evaluation of left ventricular subendoca—radial function compared with tissue Doppler imaging. J Am Coll Cardiol, 2003,42(9): 1574–1583PubMedCrossRefGoogle Scholar
  19. 19.
    Sutherland GR, Di Salvo G, Claus P, et al. Strain and strain rate imaging: a new clinclical approach to quantifying regional myocardial function. J Am Soc Echocardiogr, 2004,17(7):788–802PubMedCrossRefGoogle Scholar
  20. 20.
    Bi XJ, Deng YB, Shentu WH, et al. Assessment of left ventricular dyssynchrony in patients with hypertrophic cardiomyopathy by two-dimensional strain echocardiography. Chin J Med Imaging Technol (Chinese), 2008, 24(11):1763–1766Google Scholar
  21. 21.
    Tong C, Li CL, Song JL, et al. Assessment of right ventricular free wall longitudinal myocardial deformation using speckle tracking imaging in normal subjects. J Huazhong Univ Sci Technol: Med Health (Chinese), 2008,28(2):194–196Google Scholar
  22. 22.
    Oberholzer K, Kunz RP, Dittrich M, et al. Anthracycline-induced Cardiotoxicity: Cardiac MRI after treatment for childhood cancer. Rofo, 2004,176(9):1245–1250PubMedGoogle Scholar
  23. 23.
    Onose Y, Oki T, Mishiro Y, et al. Influence of aging on systolic left ventricular wall motion velocities along the long and short axis in clinically normal patients determined by pulse tissue Doppler imaging. J Am Soc Echocardiogr, 1999,12(11):921–926PubMedCrossRefGoogle Scholar
  24. 24.
    Langeland S, D’hooge J, Wouters PF, et al. Experimental validation of a new ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insonation angle. Circulation, 2005,112:2157–2162PubMedCrossRefGoogle Scholar
  25. 25.
    Jiang ZR, Lv HX, Liu PJ, et al. Echocardiography in assessment of cardiotoxity in breast cancer patients treated with anthracycline. Chin J Med Imaging Technol (Chinese), 2005,21(8):1209–1212Google Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag GmbH 2009

Authors and Affiliations

  • Xiaojun Bi (毕小军)
    • 1
  • Youbin Deng (邓又斌)
    • 1
  • Fanjing Zeng (曾繁静)
    • 1
  • Ying Zhu (朱 英)
    • 1
  • Yuhan Wu (伍玉晗)
    • 1
  • Ceyao Zhao (赵策瑶)
    • 1
  • Chunlei Li (黎春雷)
    • 1
  1. 1.Department of Medical Ultrasound, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations